Cerecin

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Cerecin sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Cerecin: 11 sponsored US clinical trials, none currently recruiting.

Cerecin sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 3 trials.

Top-decile sponsor footprint

Cerecin ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 1

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

NCT05408780
COMPLETED Phase 1

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

NCT04268953
COMPLETED Phase 1

Taste-masking Study for Tricaprilin in Sensory Panelists

NCT03628352
COMPLETED Phase 1

Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

NCT03063645
COMPLETED Phase 1

Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production

NCT02959710
COMPLETED Phase 1

Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production

NCT02833012
COMPLETED Phase 1

Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production

NCT02747602
COMPLETED Phase 2

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

NCT01741194
COMPLETED

Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly

NCT00660088
COMPLETED Phase 2

Tricaprilin In Age-Associated Memory Impairment

NCT00355550
COMPLETED Phase 2

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 3

Therapeutic Areas

Healthy 3
Alzheimers Disease 1

How the Cerecin early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Healthy (3 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cerecin: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cerecin sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share CerecinAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Cerecin sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cerecin sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cerecin page

11 registered trials is a research-attention snapshot, not an endorsement of Cerecin or any single study.

  • None of Cerecin's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Cerecin studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cerecin pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.